代替の Pre-mrna スプライシング RNA In Situハイブリダイゼーション法によるマウス脳のセクションでの定量的解析

Executive Industry Relevance

This method enables spatially resolved quantification of alternative splicing events in complex tissues, addressing a critical gap in target validation where bulk RNA approaches mask cellular heterogeneity. By providing isoform-specific signals at single-cell resolution in anatomically defined brain regions, it supports mechanistic de-risking of splicing-dependent targets in neuroscience drug discovery. The ability to calculate percent spliced in (PSI) values from exon inclusion and skipping signals offers a quantitative, reproducible metric for assessing target engagement and pathway modulation in preclinical models.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by linking specific splice isoforms to cell-type-specific expression patterns in disease-relevant brain regions.
• Operational Value: Provides a robust, sensitive assay system for examining alternative splicing patterns in situ within tissue slices, reducing reliance on dissociated cell models that lose spatial context.

Screening & Assay Development

• Scientific Value: Uses shock anti-static exon junction probes to generate isoform-specific hybridization signals, enabling simultaneous analysis of multiple subtypes within complex biological structures.
• Operational Value: Signal amplification technology increases detection sensitivity, producing robust signals suitable for quantitative imaging and automated analysis workflows.

Translational & Preclinical Research

• Scientific Value: Facilitates disease-relevant system analysis by mapping splicing patterns across anatomical areas such as cortex and hippocampus, supporting biomarker discovery for neuropsychiatric indications.
• Operational Value: Enables parallel processing of adjacently cut tissue sections under identical conditions, ensuring data accuracy for cross-sectional comparisons in preclinical studies.

Pipeline & Workflow Integration

The method fits within the discovery biology phase, where spatially resolved splicing data informs target selection and mechanistic understanding before assay development for high-throughput screening.

• Discovery Biology: Supports hypothesis testing by revealing cell-type-specific alternative splicing patterns that may be obscured in bulk tissue analyses.
• Screening: Generates quantitative, spatially resolved readouts (e.g., PSI values) that can inform assay design for splicing-modulating compounds.
• Analytics: Enables calculation of percent spliced in from exon inclusion and skipping signal counts, providing a normalized metric for comparing conditions across brain regions.
• Translational Research: Connects discovery findings to preclinical continuity by validating splicing changes in anatomically defined regions relevant to disease models.
• Enterprise Reuse: The probe-based approach is adaptable to multiple alternative exons, positioning it as a reusable platform for splicing analysis across diverse targets and disease areas.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by linking specific splice isoforms to defined anatomical locations, increasing confidence in target-disease relationships.
• Operational Value: Standardized protocol with built-in controls (e.g., adjacently cut slides, identical processing) enhances reproducibility across sites and users.
• Strategic Value: Supports better go/no-go decisions by providing spatially resolved efficacy and mechanism data early in the discovery pipeline.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on validated splicing expression in disease-relevant neural circuits.

Implementation Considerations

• Requires expertise in RNA in situ hybridization, tissue sectioning, and quantitative image analysis for punctate dot counting.
• Dependent on hybridization ovens, humidity control trays, and reagent systems for probe hybridization, signal amplification, and detection (e.g., Fast Red).
• Necessitates standardization across teams for slide preparation, probe incubation, and washing steps to ensure comparability of PSI calculations.
• Adaptation to new exons requires design and validation of exon junction-specific probes, with sensitivity to target sequence accessibility.
• Practical limitation: Multi-color labeling is not currently available, requiring sequential analysis on separate slides, which increases tissue sectioning and processing demands.

Biopharma FAQs